Physician profile
Robert G Curran
NPI 1700820818
$4,097.84
in general payments reported to CMS, 2019-2025
25 companies · $544 in 2025
The $544 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,202 · 2020: $816 · 2021: $329 · 2022: $312 · 2023: $438 · 2024: $457 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,439.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $420.10 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $416.67 | 2019-2024 | Jardiance, Tradjenta, Glyxambi |
| Lilly USA, LLC | $334.43 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $320.49 | 2019-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $295.71 | 2019-2023 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $278.20 | 2019-2023 | Xarelto |
| Amarin Pharma, INC. | $252.24 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $220.68 | 2023-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $208.56 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Allergan, INC. | $187.53 | 2019-2020 | |
| Glaxosmithkline, LLC. | $175.77 | 2019-2025 | Shingrix, Arexvy |
| Esperion Therapeutics, INC. | $173.76 | 2020-2025 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $115.39 | 2025 | Caplyta |
| Pfizer INC. | $109.57 | 2019 | |
| Abbott Laboratories | $100.09 | 2021-2023 | Freestyle Libre 2 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $90.55 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $79.84 | 2019-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $58.13 | 2019-2023 | |
| Eisai INC. | $54.63 | 2024-2025 | |
| Hikma Pharmaceuticals USA | $42.00 | 2022 | |
| Radius Health, INC. | $41.29 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $39.47 | 2022-2023 | Quviviq |
| Abbvie INC. | $36.53 | 2023-2024 | Linzess, Viberzi |
| Kowa Pharmaceuticals America, INC. | $30.89 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.32 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Curran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.